Search

Your search keyword '"Nakabayashi M"' showing total 582 results
Start Over Author "Nakabayashi M"
582 results on '"Nakabayashi M"'

1. Highly Reliable 4 Mb FeRAM Using a Newly Developed PLZT Capacitor With a Bi-Doped SRO Interlayer

Author

Wang, W., Eshita, T., Takai, K., Amari, S., Nakamura, K., Oikawa, M., Sato, N., Ozawa, S., Nakabayashi, M., Mihara, S., Hikosaka, Y., Saito, H., Inoue, K., and Nagai, K.

Abstract

We successfully developed a lanthanum (La)-doped Pb(Zr,Ti)O $_{\boldsymbol {\textbf {3}}}$ (PLZT)-based ferroelectric random access memory (FeRAM) with a newly developed ferroelectric capacitor (FC) employing bismuth (Bi)-doped SrRuO $_{\boldsymbol {\textbf {3}}}$ (B-SRO), aiming to improve the electrical properties and reliability of the FC. Sputter-deposited SrRuO $_{\boldsymbol {\textbf {3}}}$ , commonly used as an interlayer between the metal electrode and ferroelectric layers to improve FC characteristics, does not necessarily result in good electrical properties due to the low atomic density of SRO, typically up to 85%. To address this, we employed a B-SRO interlayer deposited by a B-SRO target with an atomic density up to 95%. FCs utilizing B-SRO exhibit significantly better electrical properties, endurance ( $\gt 10^{\boldsymbol {\textbf {14}}}$ at 90°C), and retention (approximately 10 years at 125°C) compared to FCs without B-SRO. Reliability tests based on JESD22-A108 standards, confirm that our 4Mb FeRAM with B-SRO is highly reliable and commercially available.

Published
2024
Full Text
View/download PDF

20. Model for the radiation degradation of polycrystalline silicon films

Author

Nakabayashi, M., Ohyama, H., Takakura, K., Simoen, E., and Claeys, C.

Subjects
Nuclear research -- Research, Business, Electronics, Electronics and electrical industries
Abstract

The degradation of polycrystalline silicon (Poly-Si) films, subjected to 20-MeV alpha-ray irradiation, is studied. To investigate the radiation source dependence, 20-MeV proton and 1-MeV electron irradiation have been performed as well. The damage of alpha-rays is one and three orders of magnitude larger than for protons and electrons. The radiation source dependence of the performance degradation is attributed to the difference of mass and the probability of nuclear collisions for the formation of lattice defects. It is concluded that the combination of the induced lattice defects in the grain itself and the interface state density at its boundary are mainly responsible for the degradation of the Poly-Si films by high-energy particle irradiation. The degradation of the Poly-Si films can also be explained by a finite grain-bulk dynamic resistance [r.sub.c] and a large--barrier dynamic resistance [r.sub.SCR] based on the Schottky barrier diode degradation mechanism. Index Terms--Polycrystalline silicon, radiation effects.

Published
2003

30. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

Author

Xie, W, Regan, M, Buyse, M, Halabi, S, Kantoff, P, Sartor, O, Soule, H, Clarke, N, Collette, L, Dignam, J, Fizazi, K, Paruleker, W, Sandler, H, Sydes, M, Tombal, B, Williams, S, Sweeney, C, Andren, O, Armstrong, J, Berry, D, Bolla, M, Chin, J, Chowdhury, S, Cooperberg, M, Denham, J, Di Stasi, S, Eisenberger, M, Freidlin, B, Gillessen, S, Gleave, M, Habibian, M, James, N, Jarow, J, Keating, N, Keloff, G, Klotz, L, Lukka, H, Mason, M, Miyahira, A, Mottet, N, Nakabayashi, M, Parulekar, W, Scardino, P, Scher, H, Simon, R, Simons, J, Small, E, Tangen, C, Thompson, I, Widmark, A, Wiegel, T, Wirth, M, Yeoh, E, and Zapatero, A

Subjects
Male, Oncology, Cancer Research, cancer surgery controlled study, medicine.medical_treatment, 030232 urology & nephrology, androgen deprivation therapy, localization cancer, Settore MED/24 - Urologia, law.invention, Prostatic Neoplasms randomized controlled trial (topic), Prostate cancer, 0302 clinical medicine, Randomized controlled trial, Risk Factors, law, risk factor survival analysis, Neoplasm Metastasis, skin and connective tissue diseases, disease free survival, Randomized Controlled Trials as Topic, follow up high risk patient, aged, Article, cancer, radiotherapy, correlational study, human intermediate risk patient, major clinical study, male metastasis free survival, overall survival, patient coding priority, journal prostate cancer prostatectomy treatment, duration, bio assay meta analysis, metastasis multimodality, cancer therapy, pathology, ORIGINAL REPORTS, Combined Modality Therapy, Darolutamide, 030220 oncology & carcinogenesis, Meta-analysis, Adjuvant, medicine.medical_specialty, Endpoint Determination, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Adjuvant therapy, Overall survival, Humans, Survival analysis, business.industry, Prostatic Neoplasms, medicine.disease, Survival Analysis, Surgery, business
Abstract

Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall survival (OS) could expedite the evaluation of new adjuvant therapies. Methods By June 2013, 102 completed or ongoing randomized trials were identified and individual patient data were collected from 28 trials with 28,905 patients. Disease-free survival (DFS) and metastasis-free survival (MFS) were determined for 21,140 patients from 24 trials and 12,712 patients from 19 trials, respectively. We evaluated the surrogacy of DFS and MFS for OS by using a two-stage meta-analytic validation model by determining the correlation of an intermediate clinical end point with OS and the correlation of treatment effects on both the intermediate clinical end point and OS. Results Trials enrolled patients from 1987 to 2011. After a median follow-up of 10 years, 45% of 21,140 men and 45% of 12,712 men experienced a DFS and MFS event, respectively. For DFS and MFS, 61% and 90% of the patients, respectively, were from radiation trials, and 63% and 66%, respectively, had high-risk disease. At the patient level, Kendall’s τ correlation with OS was 0.85 and 0.91 for DFS and MFS, respectively. At the trial level, R2 was 0.86 (95% CI, 0.78 to 0.90) and 0.83 (95% CI, 0.71 to 0.88) from weighted linear regression of 8-year OS rates versus 5-year DFS and MFS rates, respectively. Treatment effects—measured by log hazard ratios—for the surrogates and OS were well correlated ( R2, 0.73 [95% CI, 0.53 to 0.82] for DFS and 0.92 [95% CI, 0.81 to 0.95] for MFS). Conclusion MFS is a strong surrogate for OS for localized prostate cancer that is associated with a significant risk of death from prostate cancer.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results